Skip to main content

General Psychiatry

The US Food and Drug Administration (FDA) has ordered changes to the labeling for benzodiazepines, requiring them to include information on the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions.
In patients with comorbid chronic pain and substance use disorders, developing protocols for continuing opioid therapy are key for patient safety, W. Clay Jackson, MD, and Arwen Podesta, MD, DFASAM, DFAPA, ABIHM, told Psych Congress 2020 attendees.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
Placebos administered without deception reduced both self-reported and neural measures of emotional distress in a study published in Nature Communications.
In this video, Psych Congress 2020 cochair Charles Raison, MD, discusses the relationship between inflammation and mental illnesses, and misconceptions about the connection between the two.
Psych Congress 2020 speaker Marc E. Agronin, MD, shares strategies that mental health clinicians can use to adjust psychopharmacologic treatment and dosages for geriatric patients.
At Psych Congress Elevate, Psych Congress Steering Committee member Saundra Jain, MA, PsyD, LPC, discussed clinician burnout and using wellness practices as a possible antidote. In this podcast, she…
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, speaks with general psychiatrist Abbey Strauss, MD, MSW, about the history, chemistry, and potential use of the neurotransmitter…
In this podcast, Michael F. Myers, MD interviews fellow psychiatrists John Budin, MD, and John S. Tamerin, MD, about mental health professionals living with psychiatric illness and how their needs…
Back to Top